Leonard Paolillo - 26 Jan 2022 Form 4 Insider Report for IMPEL NEUROPHARMA INC

Role
Chief Commercial Officer
Signature
/s/ John Leaman, M.D. as attorney-in-fact
Issuer symbol
N/A
Transactions as of
26 Jan 2022
Net transactions value
$0
Form type
4
Filing time
28 Jan 2022, 16:05:45 UTC
Previous filing
26 Jul 2021
Next filing
16 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMPL Stock Option (right to buy) Award $0 +40,000 $0.000000 40,000 26 Jan 2022 Common Stock 40,000 $9.85 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 2.0833% of the total shares on February 26, 2022 and then 2.0833% of the total shares vests monthly thereafter, with 100% of the total shares vested and exercisable on January 26, 2026, subject to the reporting person's provision of service to the issuer on each vesting date.